Regentis Biomaterials draws surgeon interest at ICRS Summit in Porto, Portugal
RGNT•Regentis Biomaterials attended the Oct. 8-10, 2026, ICRS Summit in Porto, where surgeon discussions focused on its GelrinC knee implant. The company highlighted Phase II data showing about 100% greater KOOS improvement than historical microfracture controls at two years.
1. Summit discussions
Regentis Biomaterials said booth discussions with surgeons at the 8th ICRS Summit centered on GelrinC, a CE Marked, off-the-shelf hydrogel implant for knee cartilage regeneration. Management pointed to European Centers of Excellence for surgeon training and said European sites are also participating in a U.S. FDA pivotal trial.
